Vertex Kicks Off Telaprevir Pivotal Trial Next Month
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbreviated 24-week HCV therapy regimen with telaprevir could also prove itself in vast population of treatment non-responders, company says.
You may also be interested in...
Once Xenophobic, Big Pharma Looks Outside For Financing R&D
Big pharma is increasingly taking a cue from biotech by looking externally to finance internal pipelines
Once Xenophobic, Big Pharma Looks Outside For Financing R&D
Big pharma is increasingly taking a cue from biotech by looking externally to finance internal pipelines
Vertex Sells Lexiva, Agenerase Royalties For $160M
Non-core assets bring in cash for HCV push and more.